Enveda raises $311 million for nature-derived AI drugs

Summary

Enveda, a biotech startup that uses AI to identify drug candidates from plants and microorganisms, has doubled its valuation to $2 billion and raised $311 million in Series E funding. The company is currently conducting human clinical trials for candidates targeting serious skin diseases and weight maintenance following GLP-1 treatment.

Why it matters

This deal indicates that investors are still willing to accept high valuations in AI-driven drug discovery. However, as the news itself notes, no AI-discovered drug has yet received FDA approval. Enveda's nature-derived approach distinguishes it from purely in-silico competitors. Additionally, its product line adjacent to GLP-1 touches one of the hottest therapeutic areas in biotech. Valuing a company with zero approved products at $2 billion highlights that the price is based more on narrative than clinical evidence.

Highlights

• Series E round of $311 million at a $2 billion valuation, led by Catalio Capital Management with participation from Iconiq
• The product pipeline includes a serious skin disease candidate in human trials and a weight maintenance drug for post-GLP-1 use
• Founded in 2019 by Viswa Colluru, a former early-stage employee of Recursion Pharmaceuticals, to screen plants and microorganisms using AI

Critical take

This text is a thin 'Short Summary' news piece that relies heavily on the doubling of the valuation as its headline, despite acknowledging that AI has not yet delivered a single FDA-approved drug. The $2 billion valuation, lacking early-stage trial data, named endpoints, dosage information, or pharma partner commitments, reads more like a fundraising press release than a comprehensive analysis of clinical risk.